Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




First POC Genetic Test Diagnoses Lactose Intolerance Near Patient in Less Than 90 Minutes

By HospiMedica International staff writers
Posted on 05 Sep 2023

Lactose intolerance is a medical condition marked by difficulty in digesting lactose due to reduced activity or synthesis of the enzyme lactase, which breaks down lactose into its basic sugars. More...

A specific genetic variant called the −13910 C/T single nucleotide polymorphism within the MCM6 gene is linked to lactase persistence or non-persistence traits in the Caucasian population. Diagnosing lactose intolerance is crucial for implementing dietary adjustments or appropriate treatments. Now, a new point-of-care isothermal lab-on-phone lactose intolerance assay rapidly diagnoses primary lactose intolerance using direct buccal swabs or capillary blood samples with high accuracy and at low cost.

STAB VIDA (Caparica, Portugal) has developed an isothermal lab-on-phone lactose intolerance CE-IVD (In Vitro Diagnostic) marked point-of-care diagnostic assay called STAB VIDA Lda which is based on the loop-mediated isothermal amplification (LAMP) methodology followed by mutation probe-based melting curve analysis. The assay is automatically processed in real time using the Doctor Vida system, an inexpensive and portable device controlled through a user-friendly mobile app. This CE-IVD portable, handheld device facilitates isothermal nucleic acid amplification for a wide range of genetic biomarkers. Combining efficiency, accuracy, and affordability, this compact lab-on-phone lactose intolerance detection assay can prove highly valuable in managing symptoms for individuals with lactose intolerance. Moreover, it differentiates between primary and secondary forms of hypolactasia, with the former arising from genetic mutations in the enhancer region and the latter resulting from small intestine damage.

In a study, researchers evaluated the POC isothermal lab-on-phone lactose intolerance assay using buccal swabs and capillary blood samples, comparing its performance with the Sanger sequencing assay that examined the -13,910 C/T SNP in blood samples. The assay's detection limit was also determined across different sample concentrations. The findings showed that the STAB VIDA Lda isothermal lactose intolerance assay effectively identified the -13910 C/T SNP with a limit of detection of five cells per assay, achieving 98.41% accuracy for buccal swabs and 100% accuracy for capillary blood samples. The entire process, from sample collection to result retrieval, was completed in just 90 minutes, with merely two minutes of hands-on time. The detection limit achieved by the STAB VIDA Lda assay was comparable to established gold-standard methods like Sanger sequencing and PCR-based assays.

Related Links:
STAB VIDA 


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.